PTCT
Neutral signalScored 2026-10-06 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
PTC Therapeutics, Inc.
- Nom
- PTC Therapeutics, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $5.1B
- Employés
- 991
- PDG
- Matthew Klein
- Site web
- https://www.ptcbio.com
- Marché
- BBIOBMRNCAPRDYNIONSKRYS
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionally commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the Caribbean. Furthermore, in Brazil, PTC Therapeutics distributes Evrysdi as a treatment for spinal muscular atrophy (SMA) in patients aged two months and older. Leveraging its proprietary splicing platform, the company is also actively developing PTC518, a promising therapeutic candidate aimed at treating Huntington's disease. To bolster its research and development capabilities, PTC Therapeutics has established strategic collaborations, including partnerships with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation, focusing on advancing drug discovery and development research, particularly in regenerative medicine. Additionally, it collaborates with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra in the Latin America and Caribbean region. Established in 1998, PTC Therapeutics, Inc. maintains its corporate headquarters in South Plainfield, New Jersey.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 12 000 titres (~781 920,00 $ US)
- Insiders
- STEELE GLENN JR MD PHD
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$1,703,411
Avg sell (VWAP, 90d window) $66.73 vs last close $59.24 (-11.2%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$1,703,411 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-09-30
- Liquidity
- Liquid $69,035,263/day · 20d vol
- Last synced
-
2026-10-16 21:10:54
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-09 | Boulding Mark Elliott | Sell · S · 10b5-1 | 192 | $64.26 | $12,338 | Form 4 |
| 2026-10-06 | Boulding Mark Elliott | Sell · S · 10b5-1 | 435 | $64.16 | $27,910 | Form 4 |
| 2026-10-05 | Boulding Mark Elliott | Sell · S · 10b5-1 | 1,638 | $64.03 | $104,881 | Form 4 |
| 2026-09-30 | STEELE GLENN JR MD PHD | Sell · S · 10b5-1 | 12,000 | $65.16 | $781,920 | Form 4 |
| 2026-08-17 | Boulding Mark Elliott | Sell · S · 10b5-1 | 969 | $72.90 | $70,640 | Form 4 |
| 2026-08-04 | Klein Matthew B. | Sell · S · 10b5-1 | 10,292 | $68.57 | $705,722 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-10-06 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
PTCT presents a compelling investment case driven by a strong financial turnaround (net margin of 39.4%) and a clear M&A catalyst with the ST-920 Fabry gene therapy acquisition and upcoming BLA submission in Q4 2026.
The first sentence of the analysis written for PTCT on 2026-10-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $1.6M) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $1.6M) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Supports a bullish reading. Stored narrative reading is in the bullish band
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 2.35 · operating margin 49%
Suggested stop 56.04, 1.5 ATR under the last close(5.4% under the last close). Reward/risk to the next stored resistance is 2.26. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 95.9% | 92.9% | 93.0% | 93.6% | 94.0% | |
| Ebit Margin | 49.0% | -24.3% | -60.5% | -71.1% | -80.3% | |
| Ebitda Margin | 51.3% | -14.9% | -35.2% | -52.6% | -68.4% | |
| Operating Profit Margin | 49.5% | -37.5% | -46.9% | -64.0% | -69.5% | |
| Pretax Profit Margin | 40.3% | -45.0% | -74.2% | -84.1% | -96.2% | |
| Continuous Operations Profit Margin | 39.4% | -45.0% | -66.8% | -80.0% | -97.3% | |
| Net Profit Margin | 39.4% | -45.0% | -66.8% | -80.0% | -97.3% | |
| Bottom Line Profit Margin | 39.4% | -45.0% | -66.8% | -80.0% | -97.3% | |
| Current Ratio | 2.348 | 2.350 | 2.021 | 1.708 | 1.874 | |
| Quick Ratio | 2.266 | 2.310 | 1.970 | 1.654 | 1.843 | |
| Solvency Ratio | 0.232 | -0.103 | -0.144 | -0.210 | -0.237 | |
| Cash Ratio | 1.017 | 1.342 | 0.985 | 0.689 | 0.372 | |
| Price To Earnings Ratio | 8.853 | -9.543 | -3.293 | -4.900 | -5.361 | |
| Price To Earnings Growth Ratio | -0.031 | 0.219 | -0.442 | -1.011 | -0.451 | |
| Forward Price To Earnings Growth Ratio | -0.031 | 0.219 | -0.442 | -1.011 | -0.451 | |
| Price To Earnings Diluted Ratio | 9.763 | -9.543 | -3.293 | -4.900 | -5.361 | |
| Price To Earnings Diluted Growth Ratio | -0.037 | 0.219 | -0.442 | -1.011 | -0.451 | |
| Price To Book Ratio | -29.425 | -3.159 | -2.520 | -7.888 | 1,951.792 | |
| Price To Sales Ratio | 3.491 | 4.300 | 2.199 | 3.918 | 5.211 | |
| Price To Free Cash Flow Ratio | 14.693 | -19.066 | -7.392 | -5.378 | -8.337 | |
| Price To Operating Cash Flow Ratio | 8.495 | -32.211 | -13.020 | -7.677 | -11.167 | |
| Debt To Assets Ratio | 0.934 | 1.449 | 1.176 | 0.857 | 0.655 | |
| Debt To Equity Ratio | -13.185 | -2.250 | -2.723 | -4.211 | 882.729 | |
| Debt To Capital Ratio | 1.082 | 1.800 | 1.580 | 1.311 | 0.999 | |
| Long Term Debt To Capital Ratio | 1.113 | 2.086 | 1.754 | 1.381 | 0.998 | |
| Financial Leverage Ratio | -14.119 | -1.553 | -2.316 | -4.914 | 1,347.744 | |
| Working Capital Turnover Ratio | 1.656 | 1.152 | 2.077 | 1.908 | 0.770 | |
| Operating Cash Flow Ratio | 0.734 | -0.185 | -0.263 | -0.878 | -0.493 | |
| Operating Cash Flow Sales Ratio | 0.411 | -0.133 | -0.169 | -0.510 | -0.467 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.578 | 1.689 | 1.761 | 1.427 | 1.340 | |
| Debt Service Coverage Ratio | 1.210 | -0.284 | -0.806 | -2.081 | -1.268 | |
| Interest Coverage Ratio | 5.626 | -1.812 | -3.402 | -4.924 | -4.353 | |
| Short Term Operating Cash Flow Coverage Ratio | 1.249 | -0.418 | -0.815 | -4.943 | -1.204 | |
| Operating Cash Flow Coverage Ratio | 0.263 | -0.044 | -0.071 | -0.244 | -0.198 | |
| Capital Expenditure Coverage Ratio | 2.371 | -1.450 | -1.313 | -2.339 | -2.945 | |
| Dividend Paid And Capex Coverage Ratio | 2.371 | -1.450 | -1.313 | -2.339 | -2.945 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 8.746 | -42.836 | -11.194 | -10.657 | -10.555 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 95.9% | ▲3.0% | ▲2.0% |
| Ebit Margin | 49.0% | ▲73.4% | ▲86.5% |
| Ebitda Margin | 51.3% | ▲66.2% | ▲75.3% |
| Operating Profit Margin | 49.5% | ▲87.0% | ▲83.2% |
| Pretax Profit Margin | 40.2% | ▲85.3% | ▲92.1% |
| Continuous Operations Profit Margin | 39.4% | ▲84.5% | ▲89.4% |
| Net Profit Margin | 39.4% | ▲84.5% | ▲89.4% |
| Bottom Line Profit Margin | 39.4% | ▲84.5% | ▲89.4% |
| Current Ratio | 2.348 | ▼-0.002 | ▲0.288 |
| Quick Ratio | 2.266 | ▼-0.045 | ▲0.257 |
| Solvency Ratio | 0.232 | ▲0.335 | ▲0.325 |
| Cash Ratio | 1.017 | ▼-0.325 | ▲0.136 |
| Price To Earnings Ratio | 8.853 | ▲18.396 | ▲11.702 |
| Price To Earnings Growth Ratio | -0.032 | ▼-0.251 | ▲0.312 |
| Forward Price To Earnings Growth Ratio | -0.032 | ▼-0.251 | ▲0.312 |
| Price To Earnings Diluted Ratio | 9.764 | ▲19.307 | ▲12.430 |
| Price To Earnings Diluted Growth Ratio | -0.037 | ▼-0.256 | ▲0.307 |
| Price To Book Ratio | -29.425 | ▼-26.267 | ▼-411.185 |
| Price To Sales Ratio | 3.491 | ▼-0.809 | ▼-0.333 |
| Price To Free Cash Flow Ratio | 14.693 | ▲33.759 | ▲19.789 |
| Price To Operating Cash Flow Ratio | 8.495 | ▲40.706 | ▲19.611 |
| Debt To Assets Ratio | 0.934 | ▼-0.515 | ▼-0.080 |
| Debt To Equity Ratio | -13.185 | ▼-10.935 | ▼-185.257 |
| Debt To Capital Ratio | 1.082 | ▼-0.718 | ▼-0.272 |
| Long Term Debt To Capital Ratio | 1.113 | ▼-0.973 | ▼-0.354 |
| Financial Leverage Ratio | -14.119 | ▼-12.566 | ▼-279.087 |
| Working Capital Turnover Ratio | 1.656 | ▲0.504 | ▲0.143 |
| Operating Cash Flow Ratio | 0.734 | ▲0.920 | ▲0.951 |
| Operating Cash Flow Sales Ratio | 0.411 | ▲0.544 | ▲0.585 |
| Free Cash Flow Operating Cash Flow Ratio | 0.578 | ▼-1.111 | ▼-0.781 |
| Debt Service Coverage Ratio | 1.210 | ▲1.494 | ▲1.856 |
| Interest Coverage Ratio | 5.626 | ▲7.438 | ▲7.399 |
| Short Term Operating Cash Flow Coverage Ratio | 1.248 | ▲1.666 | ▲2.475 |
| Operating Cash Flow Coverage Ratio | 0.263 | ▲0.306 | ▲0.322 |
| Capital Expenditure Coverage Ratio | 2.371 | ▲3.821 | ▲3.506 |
| Dividend Paid And Capex Coverage Ratio | 2.371 | ▲3.821 | ▲3.506 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 8.746 | ▲51.582 | ▲22.046 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $6.04B | $3.47B | $2.06B | $2.74B | $2.81B | |
| Enterprise value | $7.76B | $5.16B | $3.70B | $3.92B | $3.89B | |
| EV / Sales | 4.49x | 6.40x | 3.94x | 5.61x | 7.22x | |
| EV / Op. cash flow | 10.92x | -47.92x | -23.34x | -10.99x | -15.46x | |
| EV / Free cash flow | 18.88x | -28.36x | -13.25x | -7.70x | -11.54x | |
| EV / EBITDA | 8.75x | -42.84x | -11.19x | -10.66x | -10.55x | |
| Net debt / EBITDA | 1.94x | -14.04x | -4.95x | -3.21x | -2.93x | |
| Current ratio | 2.35x | 2.35x | 2.02x | 1.71x | 1.87x | |
| Income quality | 1.04x | 0.30x | 0.25x | 0.64x | 0.48x | |
| Graham net-net | -$12 | -$20 | -$23 | -$21 | -$15 | |
| Tax burden | 98.0% | 100.0% | 90.0% | 95.2% | 101.1% | |
| Interest burden | 82.1% | 185.1% | 122.8% | 118.3% | 119.9% | |
| Working capital | $1.31B | $784.5M | $615.5M | $287.5M | $445.0M | |
| Invested capital | $1.91B | $1.10B | $1.26B | $1.25B | $1.38B | |
| Return on assets | 23.5% | -21.3% | -33.1% | -32.8% | -27.0% | |
| Operating ROA | 37.2% | -16.8% | -24.4% | -24.6% | -18.1% | |
| Return on tangible assets | 28.1% | -24.2% | -43.7% | -60.9% | -46.3% | |
| Return on equity | -332.5% | 33.1% | 76.6% | 161.1% | -36432.6% | |
| Return on invested capital | 33.4% | -21.7% | -26.3% | -30.8% | -22.7% | |
| Return on capital employed | 44.4% | -26.9% | -34.0% | -34.4% | -26.2% | |
| Earnings yield | 11.3% | -10.5% | -30.4% | -20.4% | -18.7% | |
| Free cash flow yield | 6.8% | -5.2% | -13.5% | -18.6% | -12.0% | |
| Capex / Op. cash flow | 42.2% | -68.9% | -76.1% | -42.7% | -34.0% | |
| Capex / Depreciation | 772.9% | 98.1% | 51.0% | 118.3% | 133.1% | |
| Capex / Sales | 17.3% | 9.2% | 12.9% | 21.8% | 15.8% | |
| SG&A / Sales | 20.1% | 37.3% | 35.5% | 46.7% | 53.1% | |
| R&D / Sales | 26.3% | 66.2% | 71.1% | 93.2% | 100.4% | |
| Stock comp / Sales | 4.3% | 9.2% | 14.0% | 15.8% | 19.2% | |
| Intangibles / Total assets | 16.3% | 11.8% | 24.4% | 46.2% | 41.6% | |
| Days sales outstanding | 38d | 72d | 63d | 81d | 75d | |
| Days payables outstanding | 231d | 110d | 34d | 223d | 260d | |
| Operating cycle | 443d | 219d | 233d | 259d | 254d | |
| Cash conversion cycle | 212d | 109d | 199d | 37d | -6d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-05 Comparing PTC Therapeutics (NASDAQ:PTCT) and Precigen (NASDAQ:PGEN) Precigen (NASDAQ: PGEN - Get Free Report) and PTC Therapeutics (NASDAQ: PTCT - Get Free Report) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk. Volatility and Risk Precigen has a beta of
- 2026-09-30 PTC Therapeutics (NASDAQ:PTCT) Shares Climb 4.7% – Here’s Why Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) shot up 4.7% during trading on Monday. The stock traded as high as $65.75 and last traded at $65.60. 659,183 shares were traded during mid-day trading, a decline of 52% from the average daily volume of 1,381,305 shares. The stock had previously closed at $62.67.
- 2026-09-25 PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WARREN, N.J., Sept. 25, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Sept.
- 2026-09-21 PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy – Completion of BLA submission expected in Q4 2026 – WARREN, N.J., Sept. 21, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it completed the previously announced agreement with Sangamo Therapeutics, Inc. to acquire ST-920 – a BLA-stage, one-time administered AAV gene therapy for Fabry disease.
- 2026-09-15 PTC Therapeutics, Inc. (PTCT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript PTC Therapeutics, Inc. (PTCT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2026-09-15 Amundi Raises Holdings in PTC Therapeutics, Inc. $PTCT Amundi grew its stake in shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) by 171.7% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,227 shares of the biopharmaceutical company''s stock after acquiring an additional 7,727 shares during
- 2026-09-15 California State Teachers Retirement System Has $543.82 Million Stock Position in PTC Therapeutics, Inc. $PTCT California State Teachers Retirement System raised its stake in shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) by 7,806.7% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,666,961 shares of the biopharmaceutical company''s stock after buying
- 2026-08-27 PTC Therapeutics to Participate in Upcoming Investor Conferences WARREN, N.J., Aug. 27, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Wells Fargo 21st Annual Healthcare Conference Thursday, Sept.
- 2026-08-24 PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile – 17 abstracts and presentations planned at SSIEM Symposium – – Real-world evidence demonstrates significant diet liberalization achieved with Sephience while maintaining target blood Phe levels – – Continued evidence of meaningful benefit across all patient subgroups – WARREN, N.J., Aug. 24, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that multiple Sephience™ (sepiapterin) scientific data presentations will be featured at the 2026 Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium, taking place in Helsinki, Finland, from Aug. 25-28.
- 2026-08-24 PTC Therapeutics: An Acquisition Which Could Unlock Massive Potential PTC Therapeutics offers a compelling risk-reward profile, with its valuation not fully reflecting the upside from Sephience and potential ST-920 approval. Sephience, PTCT''s lead asset, has driven rapid revenue growth, accounting for 63% of product revenue and expanding across major global markets. ST-920, acquired from Sangamo, is a late-stage gene therapy for Fabry Disease; FDA approval could significantly enhance PTCT''s valuation.